Ryan Jonathan Sitanggang is an International Cooperation Officer (ICO) at the International Unit of the HITAP Foundation. He works on strengthening HTA networks and systems across Asia through initiatives such as the Asia HTA Registry, the HTAsiaLink Strategic Plan, and regional capacity-building. His role includes managing partnerships, coordinati

Executive Summary Digital health in Korea encompasses a wide range of technologies and services yet lacks a clear legal definition. The Korea Institute for Industrial Economics & Trade (KIET) classifies digital health into hardware, software, and service categories, reflecting the diverse lan

Executive Summary Australia has a history of innovation, which is reflected in the breadth of health technologies that are increasingly available in the country’s digital health landscape. This breadth of digital health technologies can be categorised across four domains: Software as a Medical De

October 24, 2025 – At the Office of the Permanent Secretary, Ministry of Public Health (MoPH), the Environmental Economics Unit (E2U) of the Health Intervention and Technology Assessment Program Foundation (HITAP) participated in "The MoPH Greenhouse Gas Reduction Promotion Policy Announcem

66203067RM019L0Monitoring and evaluation of high cost medicines,National List of Essential Medicines,Thailand

The Health Intervention and Technology Assessment Program Foundation (HITAP) establishes the Global Research Unit (GRU), a new team created to strengthen evidence-informed policymaking in Thailand and internationally. Why GRU Matters Health technology assessment (HTA) h

COVID-19 has shown that irresepctive of national borders, the infectious disease brings multi-dimensional challenges requiring concerted global and regional efforts to address it. In contrast to the European Union and the African Union, the Association of Southeast Asian Nations (ASEAN), the regional cooperation body in Southeast Asia, has had no e

Management of advanced prostate cancer, particularly in cases of metastatic castration-resistant prostate cancer (mCRPC), typically involves first-line treatment with the chemotherapeutic agent docetaxel. Nevertheless, disease progression following docetaxel therapy remains a major challenge, as there are currently no therapeutic options listed in